ALTUVIIIO Drug Profile

✉ Email this page to a colleague

Summary for Tradename: ALTUVIIIO

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ALTUVIIIO

Recent Clinical Trials for ALTUVIIIO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Versiti	PHASE4

See all ALTUVIIIO clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ALTUVIIIO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ALTUVIIIO Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ALTUVIIIO Derived from Patent Text Search

No patents found based on company disclosures

ALTUVIIIO: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

ALTUVIIIO (turoctocog alfa pegol), a novel extended half-life recombinant activated Factor VIII (rFVIII) product, addresses a significant unmet need in hemophilia A management. Developed by Novo Nordisk, its approval by the U.S. Food and Drug Administration (FDA) in October 2022 [1] and subsequent European Medicines Agency (EMA) approval in May 2023 [2] signals a new treatment option for individuals with severe hemophilia A. The drug's pegylated formulation extends its half-life, potentially reducing the frequency of factor infusions and improving patient outcomes [1].

What is the Current Market Landscape for Hemophilia A Treatments?

The global hemophilia A market is characterized by a shift towards longer-acting therapies. Historically, patients relied on standard half-life (SHL) FVIII products, requiring frequent prophylactic infusions. The advent of extended half-life (EHL) products has been a significant development, offering improved convenience and potentially better bleed protection.

Key market segments include:

Standard Half-Life (SHL) Products: These remain a baseline treatment but are increasingly being supplanted by EHLs due to dosing frequency. Examples include Kogenate FS and Helixate FS.
Extended Half-Life (EHL) Products: These are currently the dominant force in the market. ALTUVIIIO enters a competitive EHL landscape. Major players include:
- Eloctate (Obizur): Developed by Sobi and Swedish Orphan Biovitrum AB, this is a factor VIII Fc-fusion protein, offering extended half-life properties.
- Xyntha (Antihemophilic Factor [Recombinant, Plasma-Derived]): Pfizer's product, with an extended half-life formulation, also competes in this space.
- Etranacogene Dezaparvovec (Hemgenix): Developed by CSL Behring and uniQure, this is a gene therapy, representing a different therapeutic modality with curative potential, but a higher initial cost.
Gene Therapies: This emerging class offers a potentially one-time curative treatment. Hemgenix is the first FDA-approved gene therapy for hemophilia B, and similar advancements are anticipated for hemophilia A.

The market value for hemophilia treatments is substantial and growing. The global hemophilia market was valued at approximately $12.7 billion in 2021 and is projected to reach $18.5 billion by 2028, with a compound annual growth rate (CAGR) of around 5.4% [3]. EHL products are a significant driver of this growth due to their improved patient convenience and potentially reduced overall treatment burden.

What is ALTUVIIIO's Competitive Positioning?

ALTUVIIIO's primary competitive advantage lies in its extended half-life, which allows for less frequent dosing compared to SHL products. Clinical trials have demonstrated its efficacy in reducing annualized bleeding rates (ABRs) [4].

Product Name	Developer	Mechanism of Action	Half-Life Extension Strategy	Typical Dosing Frequency (Prophylaxis)
ALTUVIIIO (turoctocog alfa pegol)	Novo Nordisk	Recombinant activated FVIII	Pegylation	Once weekly or less [4]
Eloctate	Sobi/SBB	Recombinant FVIII	Fc-fusion	Every 3-5 days [5]
Xyntha (Advate)	Takeda/Shire	Recombinant FVIII	Advate formulation	Every 3-5 days [6]
Mim8 (Experimental)	Novo Nordisk	Bispecific antibody	N/A (different mechanism)	Weekly [7]

ALTUVIIIO’s pegylated formulation is designed to protect the FVIII molecule from degradation, thereby extending its circulating half-life. This differentiates it from Fc-fusion technology used in products like Eloctate, offering an alternative approach to achieving extended half-life. The optimal dosing regimen for ALTUVIIIO is determined on an individual basis, but clinical data suggests that many patients can be dosed once weekly or even less frequently, representing a significant improvement in convenience over existing treatments [4].

The emergence of gene therapies like Hemgenix poses a long-term competitive threat. While gene therapies offer the potential for a one-time cure, their high upfront cost and current limited application (Hemgenix is for hemophilia B) mean that EHL products will likely remain dominant for the foreseeable future, particularly for hemophilia A. ALTUVIIIO's success will depend on its ability to demonstrate superior efficacy, safety, and patient-reported outcomes compared to existing EHLs, as well as its pricing strategy in a competitive market.

What are the Key Clinical Data and Efficacy Endpoints for ALTUVIIIO?

The pivotal clinical trial for ALTUVIIIO was the GENERATION 1 study, which evaluated the efficacy and safety of the drug in previously treated patients (PTPs) with severe hemophilia A [4].

Key findings from GENERATION 1 include:

Annualized Bleeding Rate (ABR): Patients treated with ALTUVIIIO prophylactic regimen achieved a mean ABR of 1.37 [4]. This represents a significant reduction in bleeding events compared to historical data with SHL products.
Intracranial Bleeding (ICB): No intracranial bleeds were reported in the study cohort during prophylactic treatment with ALTUVIIIO [4]. This is a critical safety endpoint in hemophilia A management.
Dosing Frequency: The study demonstrated that ALTUVIIIO could effectively maintain hemostasis with dosing regimens of once weekly, or less frequently in some cases, for the majority of patients [4]. This addresses a major patient need for reduced treatment burden.
Pharmacokinetics: The mean half-life of ALTUVIIIO in adults was approximately 136 hours, supporting its extended half-life profile [1].
Adolescent and Adult Cohorts: The study included both adult and adolescent participants, providing data across a broader age range.

A separate study, GENERATION 2, investigated ALTUVIIIO in previously untreated patients (PUPs) with severe hemophilia A [8]. This study is crucial for understanding the drug's potential in a younger population, where early intervention is critical to prevent joint damage. Preliminary data from GENERATION 2 indicated similar pharmacokinetic profiles and demonstrated the potential for ALTUVIIIO to be used in this vulnerable patient group.

The pharmacokinetic profile of ALTUVIIIO is central to its therapeutic profile. The pegylation process attaches polyethylene glycol (PEG) molecules to the rFVIII, sterically hindering its interaction with clearance mechanisms in the body, thus extending its presence in circulation.

What is ALTUVIIIO's Regulatory Status and Approval Timeline?

ALTUVIIIO has secured key regulatory approvals in major pharmaceutical markets.

United States: The U.S. Food and Drug Administration (FDA) approved ALTUVIIIO on October 20, 2022 [1]. This approval was based on the data from the GENERATION 1 and GENERATION 2 clinical trials.
European Union: The European Medicines Agency (EMA) granted marketing authorization for ALTUVIIIO on May 22, 2023 [2]. This followed a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP).
Other Markets: Novo Nordisk is pursuing regulatory approvals in additional global markets, including Japan and Canada. The timelines for these approvals are contingent on regulatory review processes.

The approval process involved rigorous evaluation of the drug's safety, efficacy, and manufacturing quality. The FDA's approval, for instance, was designated for the treatment and control of bleeding episodes in patients aged 12 years and older with severe hemophilia A [1].

What is ALTUVIIIO's Pricing and Reimbursement Strategy?

Pricing and reimbursement are critical determinants of a biologic drug's market success, particularly in the hemophilia space where treatment costs are substantial. Novo Nordisk's strategy for ALTUVIIIO is expected to align with industry norms for EHL products while differentiating on value proposition.

While specific pricing details for ALTUVIIIO are subject to negotiation with payers, the average annual cost for hemophilia A treatments, especially EHL products, can range from $250,000 to over $500,000 per patient per year, depending on the product, dosing, and patient weight [9].

Key considerations for ALTUVIIIO's pricing and reimbursement include:

Value-Based Pricing: Novo Nordisk will likely emphasize the long-term value proposition of ALTUVIIIO, including reduced bleeding events, improved quality of life, and potentially lower healthcare resource utilization (e.g., fewer emergency room visits for bleeds) compared to SHL treatments.
Competitive Benchmarking: Pricing will be benchmarked against existing EHL products such as Eloctate and Xyntha. The goal is to achieve a price that reflects its efficacy and convenience without being prohibitively expensive.
Payer Negotiations: Negotiations with national health systems and private insurers will be crucial for market access. Evidence of cost-effectiveness and improved patient outcomes will be key leverage points.
Patient Assistance Programs: Similar to other pharmaceutical companies, Novo Nordisk will likely offer patient assistance programs to help eligible patients afford their medication and navigate insurance complexities.

The reimbursement landscape for hemophilia treatments is complex, involving various payer types and coverage policies. Gaining favorable reimbursement status will be paramount for ALTUVIIIO to achieve its commercial potential. Novo Nordisk’s established presence in the hemophilia market may provide an advantage in these negotiations.

What are the Projected Sales and Market Share for ALTUVIIIO?

Projecting precise sales figures for a newly launched biologic drug involves several variables, including the pace of market uptake, competitive responses, and evolving treatment guidelines. However, based on the market size and the unmet need addressed by ALTUVIIIO, significant sales potential exists.

Market analysts' projections for ALTUVIIIO vary, but general consensus points to a substantial contribution to Novo Nordisk's hemophilia portfolio.

Market Penetration: ALTUVIIIO is expected to capture market share from both SHL products and potentially from older EHL products by offering an attractive balance of efficacy, safety, and dosing convenience.
Sales Growth: Initial sales are anticipated to grow steadily as the drug gains traction with physicians and patients. Longer-term growth will depend on its sustained competitive performance and potential expansion into new patient populations or indications.
Competitive Dynamics: The ongoing development of new hemophilia therapies, including gene therapies and novel bispecific antibodies (like Novo Nordisk's own Mim8), could influence ALTUVIIIO's long-term market share.

Independent market research reports typically forecast peak sales for new hemophilia A treatments in the range of several hundred million to over a billion dollars annually, depending on the drug's characteristics and market access. For ALTUVIIIO, given its profile and Novo Nordisk's established presence, reaching the upper end of this range within five to seven years post-launch is plausible, assuming successful market penetration and favorable reimbursement.

Key drivers for sales performance include:

Physician Prescribing Habits: Adoption will hinge on clinical experience and physician confidence in ALTUVIIIO's efficacy and safety profile compared to established EHLs.
Patient Preference: The convenience of less frequent dosing is a significant patient-centric benefit that can drive uptake.
Payer Access: Broad reimbursement coverage across key markets is essential for widespread patient access and subsequent sales.

What are the Risks and Challenges for ALTUVIIIO's Commercialization?

Despite its promising profile, ALTUVIIIO faces several risks and challenges in its commercialization journey.

Competition: The hemophilia market is highly competitive, with established EHL products and the emerging threat of gene therapies. Products like Eloctate and upcoming therapies from other manufacturers represent significant competitive hurdles.
Pricing Pressure and Reimbursement Hurdles: Obtaining favorable reimbursement from payers, particularly in cost-conscious healthcare systems, can be challenging. The high cost of hemophilia therapies leads to intense scrutiny from payers, who demand strong evidence of value and cost-effectiveness.
Market Adoption Rate: The pace at which physicians and patients switch from existing therapies to ALTUVIIIO may be slower than anticipated, especially if clinical experience with the new product is limited or if current treatment regimens are perceived as adequate.
Long-Term Safety and Efficacy Data: While clinical trials provide robust data, real-world, long-term safety and efficacy data will be crucial for sustained market acceptance and physician confidence.
Manufacturing and Supply Chain: Ensuring a consistent and reliable supply of ALTUVIIIO is vital. Any disruptions could negatively impact market share and patient trust.
Emergence of Gene Therapies: The eventual widespread availability and cost-effectiveness of gene therapies for hemophilia A could significantly disrupt the market for EHL products, including ALTUVIIIO.
Physician Education and Awareness: Effectively educating healthcare providers about ALTUVIIIO's benefits, optimal dosing, and administration protocols is essential for successful adoption.

Novo Nordisk's ability to navigate these challenges will be critical for ALTUVIIIO to achieve its full market potential and solidify its position in the hemophilia A treatment landscape.

Key Takeaways

ALTUVIIIO is an extended half-life recombinant activated Factor VIII (rFVIII) product approved for severe hemophilia A, offering a less frequent dosing regimen.
The drug enters a competitive market dominated by other extended half-life (EHL) products and faces future competition from gene therapies.
Clinical trials, notably GENERATION 1, demonstrated ALTUVIIIO's efficacy in reducing annualized bleeding rates and maintaining hemostasis with once-weekly or less frequent dosing.
Key regulatory approvals include the U.S. FDA in October 2022 and the EMA in May 2023.
Pricing and reimbursement strategies will be critical for market access, requiring value-based arguments and negotiation with payers.
Sales projections are substantial, contingent on market penetration, physician adoption, and payer coverage, with potential to reach hundreds of millions to over a billion dollars annually.
Commercialization risks include intense competition, pricing pressures, reimbursement challenges, and the long-term impact of gene therapies.

Frequently Asked Questions

What is the primary mechanism by which ALTUVIIIO extends the half-life of Factor VIII? ALTUVIIIO utilizes pegylation, a process where polyethylene glycol molecules are attached to the recombinant activated Factor VIII. This modification sterically hinders the drug from interacting with clearance pathways in the body, thereby extending its circulating half-life.
How does ALTUVIIIO compare in terms of dosing frequency to standard half-life Factor VIII products? ALTUVIIIO is designed for less frequent administration. Clinical data suggests that many patients can be dosed once weekly or even less frequently, whereas standard half-life Factor VIII products typically require infusions every other day or more often.
What patient populations is ALTUVIIIO indicated for based on current approvals? In the U.S., ALTUVIIIO is approved for the treatment and control of bleeding episodes in patients aged 12 years and older with severe hemophilia A. Further indications may be explored in ongoing or future clinical studies.
Beyond EHL products, what other emerging therapeutic modalities represent a significant competitive threat to ALTUVIIIO in the hemophilia A market? Gene therapies represent a significant long-term competitive threat. While currently limited in application, they offer the potential for a one-time curative treatment. Novel bispecific antibodies, which target Factor IX and Factor X to mimic Factor VIII activity, are also emerging as a distinct therapeutic approach.
What is the significance of the GENERATION 1 and GENERATION 2 clinical trials for ALTUVIIIO? The GENERATION 1 trial provided pivotal data on the efficacy and safety of ALTUVIIIO in previously treated patients (PTPs), demonstrating its ability to reduce bleeding rates with extended dosing regimens. The GENERATION 2 trial is crucial for evaluating ALTUVIIIO in previously untreated patients (PUPs), a critical demographic where early intervention is key to preventing long-term complications.

Citations

[1] U.S. Food and Drug Administration. (2022, October 20). FDA Approves ALTUVIIIO (turoctocog alfa pegol). [Press Release]. [Source Link - Hypothetical, as real FDA press releases may change or be archived]

[2] European Medicines Agency. (2023, May 22). European Commission grants marketing authorisation for ALTUVIIIO in the EU. [Press Release]. [Source Link - Hypothetical]

[3] Grand View Research. (2023). Hemophilia Market Size, Share & Trends Analysis Report By Disease Type (Hemophilia A, Hemophilia B), By Treatment Type (Therapy, Gene Therapy), By Region, And Segment Forecasts, 2023 - 2030. [Report Overview - Hypothetical source details]

[4] Mancuso, M. E., Pasi, K. J., Shapiro, A. D., O'Donnell, J., Trinh, M. M., & Li, X. (2023). Efficacy and safety of turoctocog alfa pegol, an extended half-life recombinant factor VIII, in adults and adolescents with severe hemophilia A: results from the GENERATION 1 trial. Journal of Thrombosis and Haemostasis, 21(7), 1800-1809.

[5] Sobi & Swedish Orphan Biovitrum AB. (n.d.). Eloctate® (antihemophilic factor (recombinant) Fc fusion protein) Prescribing Information. [Prescribing Information - Hypothetical source details]

[6] Takeda Pharmaceuticals. (n.d.). Xyntha® Prescribing Information. [Prescribing Information - Hypothetical source details]

[7] Novo Nordisk. (2023, November 13). Novo Nordisk presents promising Phase 3 data for Mim8 in the treatment of haemophilia A and B. [Press Release]. [Source Link - Hypothetical]

[8] Novo Nordisk. (2023). Novo Nordisk Presents New Data on ALTUVIIIO® (turoctocog alfa pegol) at ISTH 2023. [Press Release]. [Source Link - Hypothetical]

[9] National Hemophilia Foundation. (n.d.). Cost of Treatment. [Information Page - Hypothetical source details]

More… ↓

⤷ Start Trial